Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Net Income (2016 - 2025)

ImmunityBio (IBRX) has disclosed Net Income for 12 consecutive years, with -$62.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 4.7% to -$62.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$351.5 million, a 15.03% increase, with the full-year FY2025 number at -$351.5 million, up 15.03% from a year prior.
  • Net Income was -$62.0 million for Q4 2025 at ImmunityBio, up from -$67.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$59.2 million in Q4 2024 to a low of -$233.4 million in Q4 2023.
  • A 5-year average of -$105.8 million and a median of -$95.2 million in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: tumbled 345.28% in 2021, then soared 74.65% in 2024.
  • ImmunityBio's Net Income stood at -$91.6 million in 2021, then decreased by 18.32% to -$108.3 million in 2022, then crashed by 115.47% to -$233.4 million in 2023, then skyrocketed by 74.65% to -$59.2 million in 2024, then dropped by 4.7% to -$62.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Net Income are -$62.0 million (Q4 2025), -$67.3 million (Q3 2025), and -$92.6 million (Q2 2025).